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Hormone replacement therapy is associated with
gastro-oesophageal reflux disease: a retrospective
cohort study
Helen Close1*, James M Mason1, Douglas Wilson1 and A Pali S Hungin2
Abstract
Background: Oestrogen and progestogen have the potential to influence gastro-intestinal motility; both are key
components of hormone replacement therapy (HRT). Results of observational studies in women taking HRT rely on
self-reporting of gastro-oesophageal symptoms and the aetiology of gastro-oesophageal reflux disease (GORD)
remains unclear. This study investigated the association between HRT and GORD in menopausal women using
validated general practice records.
Methods: 51,182 menopausal women were identified using the UK General Practice Research Database between
1995–2004. Of these, 8,831 were matched with and without hormone use. Odds ratios (ORs) were calculated for
GORD and proton-pump inhibitor (PPI) use in hormone and non-hormone users, adjusting for age, co-morbidities,
and co-pharmacy.
Results: In unadjusted analysis, all forms of hormone use (oestrogen-only, tibolone, combined HRT and
progestogen) were statistically significantly associated with GORD. In adjusted models, this association remained
statistically significant for oestrogen-only treatment (OR 1.49; 1.18–1.89). Unadjusted analysis showed a statistically
significant association between PPI use and oestrogen-only and combined HRT treatment. When adjusted for
covariates, oestrogen-only treatment was significant (OR 1.34; 95% CI 1.03–1.74). Findings from the adjusted model
demonstrated the greater use of PPI by progestogen users (OR 1.50; 1.01–2.22).
Conclusions: This first large cohort study of the association between GORD and HRT found a statistically significant
association between oestrogen-only hormone and GORD and PPI use. This should be further investigated using
prospective follow-up to validate the strength of association and describe its clinical significance.
Keywords: Gastro-oesophageal reflux disease, Hormone replacement therapy, Menopause
Background
Gastro-oesophageal reflux disease (GORD) is a common
relapsing disorder largely caused by repeated exposure
in the lower oesophagus to the retrograde flow of gastric
contents [1]. Epidemiological studies have shown that
reflux is experienced by 3–20% of the population at least
weekly [2-4]. It is one of the most prevalent conditions
seen in primary care [5,6] and is costly in terms of
pharmacological therapy and investigations [5]. Symp-
toms of GORD, including heartburn, regurgitation and
nausea, are associated with a reduced quality of life [7,8].
The aetiology of GORD remains unclear, although re-
search has identified the main risk factors as heredity [9],
increased body mass index (BMI) [10] and tobacco
smoking [11]. Some studies indicate a stronger associ-
ation between GORD and obesity in females than males,
suggesting a link with female sex hormones [12]. This hy-
pothesis is supported by in-vitro and clinical data which
suggest an indirect action of sex hormones on GI motil-
ity [13-16], evidence of reduced upper GI motility during
the menstrual cycle [17] and reduced oesophageal
sphincter pressure during pregnancy [18]. Recent studies
suggest that hormone replacement therapy (HRT) may
be associated with GORD in post-menopausal women
[19]. A recent Swedish cohort study of female twins sug-
gests that oestrogen-only HRT is an independent risk
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factor for GORD symptoms [20] (OR 1.32; 95% CI 1.18–
1.47). A large US randomised controlled trial reported a
similar association among post-menopausal women with
hysterectomy [21], findings mirrored in a US cohort
study of post-menopausal registered nurses [22]. Al-
though a Norwegian case–control study indicated that
obesity increases the influence of oestrogen use upon
GORD (OR 2.3; 95%CI 1.1–4.8), it is difficult to draw
firm conclusions given the small numbers [12]. These
findings contrast with in-vitro evidence suggesting that
progestogen use may play a greater role than oestrogen
in upper GI motility [23]. Furthermore, these European
and US studies relied on self-reporting of symptoms and
did not take into account time from onset of menopausal
symptoms. In light of these results, the goal of this study
was to establish the extent of the association between
upper GI symptoms and the use of forms of HRT, and
the relative importance of oestrogen compared with pro-
gestogen in the UK population.
Methods
A retrospective cohort study was designed and conducted,
accessing records from the General Practice Research
Database (GPRD). The GPRD provides anonymised access
to electronic primary care medical records and prescrip-
tion data for a representative 6% of the UK population
[24], and has been extensively validated as a reliable
source of GORD information [25]. Diagnoses were identi-
fied using Read codes and prescriptions using Prescription
Pricing Authority (PPA) codes; all codes for GORD symp-
toms, outcomes, medications and covariates are available
on request. Data were accessed under the Medical Re-
search Council licence for academic groups (protocol
reference 07109).
Disease definitions
Menopausal symptoms were defined using a wide range
of diagnostic and referral codes indicating menopause or
menopausal symptoms such as “menopause” and “syn-
drome menopausal”. Gastro-oesophageal outcomes were
categorised in two ways firstly using diagnostic codes
specific to GORD (ICD 10 category K21), for example
“gastro-oesophageal reflux”, and secondly including Bar-
rett’s Oesophagus and more general codes indicative of
symptoms of GORD such as ‘reflux oesophagitis’ and
‘waterbrash’. In recognition of the reported lack of stand-
ardisation of GORD recording [25] in general practice;
we also investigated the association between proton-
pump inhibitor (PPI) and hormone use.
Cohort selection
The original GPRD cohort contained complete records
for 102,602 women with a recorded diagnosis of meno-
pause aged between 40–70 at menopause diagnosis (T0).
Diagnosis occurred within the cohort window of 01/01/
1995 – 31/12/2004 (largely avoiding the subsequent re-
duction in HRT following reports of increased cancer
and cardiovascular risk). Patients with less than
24 months of continuous GP registration were excluded,
as were patients with malignancy or pregnancy recorded
within the study window. The study window for identify-
ing the cohort was defined as two years from menopause
diagnosis (T0 +/− 24 months). Patients who commenced
HRT more than 2 years before or after the first record of
menopause were excluded, thus a cohort of N= 51,182
women with a record of menopause were within the
study window. A sub-cohort of hormone users were
matched, according to calendar year, age at menopause,
socio-economic status of GP practice, and date closest to
menopause, with one user for every two non-users.
In addition to GORD, records were evaluated for hys-
terectomy, osteoarthritis, non-steroidal anti-inflammatory
drugs (NSAIDs), bisphosphonates and calcium supple-
ment use at menopause diagnosis. Limited by variable
reporting within the GPRD, smoking and alcohol status
were crudely categorized by “non-user”, “user” or “ex-
user” at menopause. Mean BMI was calculated using all
BMI readings (kg/m2) within the study window and cate-
gorized as underweight (<18.5), normal (18.5 to 24.9),
overweight (25 to 29.9), obese (30 to 39.9), morbidly
obese (≥40). GP practices were allocated a quintile score
for socioeconomic status based in the Index of Multiple
Deprivation (IMD) [26].
Drug exposure definitions
Hormone use incorporated the following proprietary and
generic classifications: Combined hormone (conjugated
oestrogen with progestogen; estradiol with progestogen);
oestrogen-only (oestradiol only; oestradiol, oestriol and
oestrone; oestriol only; oestropipate only; conjugated
oestrogens only); tibolone; and progestogen (other than
for contraception; dydrogesterone; medroxyprogesterone;
norethisterone; progesterone). For analytic purposes, the
term ‘All hormone (AH)’ incorporates all of the above
categories; sensitivity analysis reports on the differences
between categories.
Bisphosphonates incorporated bisphosphonates and
other drugs affecting bone metabolism including alen-
dronic acid. Calcium supplements comprised calcium
gluconate, calcium lactate, and calcium carbonate pre-
parations. Non-steroidal anti-inflammatory drugs com-
prised all NSAIDs. Exposure to these drugs was
defined as at least one prescription record in the time
window of 2 years prior to or at menopause diagnosis.
Proton pump inhibitors (PPIs) comprised esomepra-
zole, lansoprazole, omeprazole, pantoprazole, and rabe-
prazole sodium. Use of PPI (categorised as yes/no) was
identified both before and after hormone exposure.
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Analysis
The relative risk of GORD or PPI use was estimated as
an odds ratio (OR) for hormone use compared to non
use. Models were subsequently adjusted for demo-
graphic, comorbidity and drug exposures variables. Data
management and manipulation was performed using
Stata/IC 10. Binomial logistic regression analyses used
SPSS v15; the response variable was the presence or ab-
sence of GORD or PPI use, and independent variables
were either categorical, ordinal or continuous as appro-
priate. The analysis fitted odds ratios for each of the in-
dependent variables with 95% confidence intervals (CIs).
The Wald statistic was used to indicate the statistical
significance of each fitted logit coefficient (different from
zero) corresponding to each independent variable.
Simple regression examined the unadjusted strength of
association between each different form of HRT and
GORD. Cases and controls were then matched accord-
ing to calendar year, age at menopause, socio-economic
status of GP practice, and date closest to menopause,
and simple matched analysis was conducted. The
matched dataset was then used to conduct multiple re-
gression analysis taking into account smoking (never/
ever/ex), alcohol (never/ever/ex), BMI (subdivided as
<18.5, 18.5–24.9, 25–29.9, 30–39.9) and current drug
use (NSAID use, calcium supplements and bisphospho-
nate, duration subdivided into <30 days, and ≥30 days).
After extensive exploration, five models for PPI-use and
for GORD response were chosen for further detailed
analysis on the basis that they allowed for full explor-
ation of the relative effects of risk factors. Model A fea-
tured simple regression (unadjusted estimates). Models
B to E featured multiple regression (adjusted estimates).
Model B incorporated NSAID use (never/ever) calcium
use (never/ever), bisphosphonate use (never/ever), BMI,
alcohol, and smoking; Model C incorporated NSAID use
(never/ever), calcium use (never/ever), bisphosphonates
(never/ever); Model D incorporated Model B but
exchanged never/ever drug use for drug duration
(<30 days, and ≥30 days) plus BMI, alcohol and smok-
ing; Model E incorporated Model D minus BMI, alcohol
and smoking. All subgroup analyses were prospectively
planned, informed by previous research and clinical ex-
pertise. Smoking, alcohol, and BMI had high proportions
of missing or unreliable (out of range) data; the final
models reported did not include these variables.
Results
Among 51,182 women with medical records taken from
414 general practices, 22,101 women (43%) were hor-
mone users and 29,081 (57%) were non-users. Overall,
users and non-users had clinically similar baseline
demographic characteristics, although non-users of hor-
mones were slightly less likely to use NSAIDs, and a
higher proportion of oestrogen-only users had under-
gone hysterectomy (Table 1). A total of 23,210 women
(45%) had a record of hysterectomy while 21,835 women
(43%) had at least one record of pregnancy ever. The
mean age of commencing hormone replacement was
49.7 years and the mean exposure duration was 5.4 years.
The most common hormone replacement was combined
oestrogen and progestogen; 68.3% of women were
exposed to more than one type of hormone and 1% of
users stopped taking hormone after one prescription.
A total of 42,724 (84%), women had ever been recorded
as having GORD symptoms, with a total of 18.5% of all
consultations coded as ‘Dyspepsia’, and 3.3% of consulta-
tions coded as ‘Gastro-oesophageal Reflux Disease’. The
majority of these occurrences were post-menopause. Prior
to the study window (pre-menopause), overall 11881
women (23%) consulted their GP for GORD symptoms;
GORD reporting rates were comparable between groups
prior to hormone exposure (25% of oestrogen-only and
tibolone users reported GORD prior to hormone exposure
compared to 22% of combined hormone and 23% of pro-
gestogen users and non-hormone users).
Table 2 shows the simple analysis (unadjusted for
other patient characteristics) of each form of hormone
and the strength of their association with GORD, com-
paring unmatched with matched data. All forms of hor-
mone were statistically significantly associated with
reported GORD symptoms (Table 2) both in the un-
matched and the matched groups.
Adjusted analyses (shown in Table 3) explored the
relative strength of association between different forms
of hormone and GORD, taking into account certain pa-
tient characteristics. This showed a statistically signifi-
cant independent association between oestrogen-only
use and GORD (OR 1.49, 95% CI 1.18–1.89, p = 0.001)
when taking into account the relative effect of other risk
factors (NSAID, bisphosphonate and calcium use). Other
unadjusted associations between hormone therapies and
GORD did not persist when models were adjusted for
these risk factors. Previously known independent risk
factors for GORD were confirmed; the models provide
evidence of the independent but varying influence of
NSAID use and calcium on GORD.
A total of 35639 women (34.7%) were ever-users of
PPIs with a mean number of 64 PPI prescriptions. Pre-
menopause, the use of PPI prescriptions was comparable
across hormone and non-hormone groups for approxi-
mately 6% of women.
Simple regression, unmatched and matched analyses
(Table 2) showed a consistent statistically significant asso-
ciation between PPI use and oestrogen-only use only (OR
1.46, p = 0.001 and OR 1.42, p = 0.007 respectively). This
association remained present in adjusted analysis (OR
1.34, 95% 1.03–1.74, p = 0.027, Table 4). In unadjusted
Close et al. BMC Gastroenterology 2012, 12:56 Page 3 of 9
http://www.biomedcentral.com/1471-230X/12/56
Table 1 Cohort baseline at menopause diagnosis according to use or non-use of hormone
Characteristics Oestrogen Users
N= 7678)
Tibolone Users
N= 1539
Combined Hormone users
N= 9137
Progestogen Users
N= 3747
Non-users
N= 29081 (%)
Age (y) 40 to 49 2987 (39%) 275 (18%) 3941 (43%) 2212 (59%) 9795 (34%)
50 to 59 3229 (42%) 902 (59%) 4464 (49%) 1348 (36%) 13189 (45%)
60 to 70 1462 (19%) 362 (24%) 732 (8%) 187 (5%) 6097 (21%)
Mean (SD) 52.6 (7.23) 55.1 (6.16) 50.9 (5.54) 49.1 (5.44) 53.4 (7.24)
Alcohol user1 Non-user 583 (16%) 104 (14%) 617 (14%) 279 (16%) 2243 (17%)
User 3097 (83%) 615 (85%) 3840 (85%) 1437 (83%) 10386 (81%)
Ex-user 69 (2%) 7 (1%) 57 (1%) 20 (1%) 197 (2%)
Smoker2 Non-user 2526 (53%) 501 (54%) 2966 (52%) 1208 (54%) 9719 (59%)
User 1452 (30%) 279 (30%) 1817 (32%) 720 (32%) 4010 (24%)
Ex-user 800 (17%) 149 (16%) 955 (17%) 317 (14%) 2766 (17%)
BMI3 Underweight 76 (2%) 13 (1%) 86 (2%) 24 (1%) 222 (1%)
Normal 1928 (41%) 374 (40%) 2524 (44%) 833 (39%) 5771 (37%)
Overweight 1606 (34%) 338 (36%) 1943 (34%) 627 (30%) 5038 (32%)
Obese 1004 (21%) 194 (21%) 1034 (18%) 530 (25%) 3812 (25%)
Morbidly Obese 121 (3%) 25 (3%) 122 (2%) 104 (5%) 702 (5%)
Mean (SD) 26.9 (5.47) 27.1 (5.80) 26.4 (5.17) 27.7 (6.39) 27.7 (6.11)
Practice IMD4 0 1759 (23%) 311 (20%) 1988 (22%) 832 (22%) 6112 (21%)
1 1252 (16%) 248 (16%) 1609 (18%) 702 (19%) 5287 (16%)
2 1578 (21%) 255 (17%) 1804 (20%) 764 (20%) 5743 (20%)
3 1453 (19%) 344 (22%) 1751 (19%) 731 (20%) 5757 (20%)
4 1636 (21%) 381 (25%) 1985 (22%) 718 (19%) 6182 (21%)
Hysterectomy 3470 (45%) 165 (11%) 462 (5%) 472 (13%) 3229 (11%)
NSAID use 4191 (55%) 879 (57%) 4750 (52%) 2242 (60%) 13993 (48%)
Bisphophonates 188 (2%) 57 (4%) 192 (2%) 53 (2%) 827 (3%)
Calcium supplements 419 (5%) 118 (8%) 477 (5%) 113 (3%) 1707 (6%)
GORD symptoms5 1915 (25%) 387 (25%) 2031 (22%) 859 (23%) 6689 (23%)
PPI use5 564 (7%) 88 (6%) 555 (6%) 239 (6%) 1947 (7%)
154% of patients had missing data.
241% of patients had missing data.
343% of patients had missing data.
4Index of Multiple Deprivation (IMD) based on practice post-code. Quintile 0 is the least deprived, quintile 4 is the most deprived.
5Prior to menopause.
Table 2 Risk of GORD and PPI use among hormone replacement therapy users: simple regression
All hormone users Oestrogen-only
users
Tibolone users Combined HRT
users
Progestogen
users
No. of hormone users Unmatched cohort 22101 9137 7678 1539 3747
Matched1 cohort 2777 950 167 1190 470
GORD OR (95%CI) p Unmatched cohort 1.23 (1.18–1.27)
<0.001
1.36 (1.29–1.43)
<0.001
1.26 (1.23–1.51)
<0.001
1.15 (1.09–1.20)
<0.001
1.11 (1.04–1.20)
0.040
Matched cohort 1.29 (1.12–1.48)
<0.001
1.59 (1.27–2.0)
<0.001
1.14 (1.06–1.22)
<0.001
1.14 (0.92–1.43)
0.234
1.15 (1.06–1.23)
<0.001
PPI2 OR (95%CI) 3p Unmatched cohort 1.38 (1.19–1.60)
<0.001
1.46 (1.16–1.84)
0.001
1.52 (0.92–2.50)
0.100
1.41 (1.10–1.80)
0.006
1.06 (0.71–1.59)
0.760
Matched cohort 1.30 (1.15–1.52)
0.001
1.42 (1.10–1.84)
0.007
1.38 (0.48–3.95)
0.549
1.21 (0.95–1.54)
0.121
1.18 (0.72–1.95)
0.512
1. Uses and non-users were matched according to calendar year, age at menopause, socio-economic status of GP practice, and date closest to menopause.
2. Ever PPI use within study window.
3. P-values: comparison of binary variables by adjusted χ2 test; continuous variables by Student’s t-test; multiple category variables by χ2 test adjusted for trend.
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models, the association between GORD or PPI use and
progestogen was not statistically significant, however, the
association was significant (OR 1.50, 95% CI 1.01–2.22,
p = 0.044) in the adjusted analysis. The previously known
association between NSAID use and PPI use was con-
firmed but small numbers of users of calcium supple-
ments and bisphosphonates gave non-significant findings.
Preliminary unadjusted models including BMI, alcohol
and smoking had large numbers of missing data. These
variables poorly fitted any model of GORD or PPI use in
unadjusted analyses. When adjusted models of GORD
were analysed with BMI, alcohol and smoking as inde-
pendent variables, similarly none fitted at a statistically
significant level. In unadjusted analysis, there was a
small but unimportant association between BMI and PPI
use (OR 1.04, 95% CI 1.01–1.056, p = 0.001). Alcohol use
(OR 4.17, 95% CI 1.20–14.52, p = 0.025) was an
additional independent factor in a model of PPI use
among combined hormone users, this may be a chance
finding in a model involving small numbers.
Discussion
Within the range of models tested, there was a consist-
ent association between GORD or PPI-use and
oestrogen-only hormone replacement. Our evaluation
represents the first direct controlled comparison of hor-
mone types for a clinically meaningful GORD diagnosis
in a UK population, allowing for multiple hypothesis
testing. The large sample size enabled extensive model
refinement and subgroup analyses in three ways. Firstly,
simple analyses allowed us to identify the potential asso-
ciation between different forms of HRT and GORD re-
gardless of other patient characteristics. This was the
first step in understanding the differences between forms
Table 3 Risk of GORD among hormone replacement users: multiple regression
Oestrogen-only users
No. of GORD cases
OR (95% CI) P
Tibolone users
No. of GORD cases
OR (95% CI) P
Combined HRT users
No. of GORD cases
OR (95% CI) P
Progestogen users
No. of GORD cases
OR (95% CI) P
GORD
Hormone 144 21 137 56
Non-hormone 572 572 572 572
OR (95% CI) p 1.49 (1.18–1.89) 0.001 0.79 (0.45–1.4) 0.419 1.09 (0.87–1.37) 0.445 1.29 (0.90–1.84) 0.170
NSAIDs <30d
Hormone 23 3 22 12
Non-hormone 99 99 99 99
OR (95% CI) p 1.52 (1.09–2.12) 0.014 1.08 (0.48–2.48) 0.848 1.25 (0.92–1.71) 0.150 1.09 (0.68–1.74) 0.718
NSAIDs ≥30d
Hormone 75 14 62 21
Non-hormone 233 233 233 233
OR (95% CI) p 2.06 (1.59–2.66)< 0.001 3.42 (1.22–9.64) 0.020 1.97 (1.56–2.50) < 0.000 1.14 (0.77–1.68) 0.520
Calcium <30d
Hormone 1 0 0 0
Non-hormone 10 10 10 10
OR (95% CI) p 0.56 (0.13–2.41) 0.439 1.58 (0.31–8.02) 0.582 0.49 (0.11–2.06) 0.325 4.14 (1.40–12.27) 0.010
Calcium ≥30d
Hormone 11 2 11 0
Non-hormone 37 37 37 37
OR (95% CI) p 2.15 (1.26–3.66) 0.005 1.88 (0.53–6.72) 0.330 1.99 (1.18–3.36) 0.010 1.64 (0.523–5.07) 0.393
Bisphosphonate <30d
Hormone 0 0 1 0
Non-hormone 3 3 3 3
OR (95% CI) p 0.56 (0.06–4.80) 0.592 - (−) 0.999 1.11 (0.29–4.26) 0.886 - (−) 0.999
Bisphosphonate ≥30d
Hormone 6 0 4 0
Non-hormone 12 12 12 12
OR (95% CI) p 0.93 (0.43–2.04) 0.865 0.84 (0.15–4.75) 0.845 0.69 (0.27–1.79) 0.445 0.75 (0.13–4.27) 0.744
This table shows the number of prospective GORD positive events for hormone replacement use and non-use.
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of HRT and showed that oestrogen-only HRT presented a
possible association with GORD. Secondly, adjusted ana-
lysis allowed us to confirm that, even when accounting
for known risk factors (NSAID use and other medica-
tions), there was an association between oestrogen-only
HRT and GORD. Thirdly, we matched cases with controls
according to year, age, and socio-economic status in
order to account for the effect of these variables upon
the incidence of GORD. This further supports the pos-
sible association between oestrogen-only HRT and
GORD. This study is also the first to compare progesto-
gen only with hormone replacement therapy. Although
progestogen was independently associated with PPI use,
this was not consistent across simple and adjusted ana-
lyses or across GORD groups but the reasons for this are
unclear. It was previously thought that progestogen may
have a relaxing effect on lower oesophageal sphincter
tone. More recent work suggests that oestrogen increases
nitric oxide synthesis, which results in smooth muscle
relaxation in both human [27] and animal models [28]
and may, therefore, be involved in the pathogenesis of
GORD. Our findings suggest that oestrogen-only hor-
mone has a stronger independent association with
GORD than progestogen, refuting earlier in-vitro studies
suggesting progestogen was the most important hor-
mone in GORD aetiology.
There is a well established association between
NSAIDs and GORD, which our study suggests may be
higher in magnitude with tibolone use although our
findings are not statistically significant. Tibolone has
oestrogenic, progestogenic, and androgenic effects which
act to prevent bone loss. It has been associated with
decreased levels of fibrinogen, factor VII, plasminogen
activator inhibitor 1, homocysteine, and tissue plasmino-
gen activator and with increased levels of C-reactive pro-
tein, antithrombin III, and D-dimer [29]. However, it is
Table 4 Risk of PPI use among hormone replacement users: multiple regression
Oestrogen-only users
No. of GORD cases
OR (95% CI) P
Tibolone users
No. of GORD cases
OR (95% CI) P
Combined HRT users
No. of GORD cases
OR (95% CI) P
Progestogen users
No. of GORD cases
OR (95% CI) P
PPI
Hormone 110 21 116 49
Non-hormone 467 467 467 467
OR (95% CI) p 1.34 (1.03–1.74) 0.027 0.76 (0.43–1.37) 0.367 1.15 (0.90–1.47) 0.250 1.50 (1.01–2.22) 0.044
NSAIDs <30d
Hormone 22 2 18 10
Non-hormone 81 81 81 81
OR (95% CI) p 1.57 (1.09–2.26) 0.016 0.83 (0.34–2.08) 0.700 1.57 (1.13–2.19) 0.008 1.15 (0.67–1.98) 0.606
NSAIDs ≥30d
Hormone 56 16 58 24
Non-hormone 200 200 200 200
OR (95% CI) p 2.02 (1.52–2.69)< 0.001 2.55 (1.41–4.63) 0.002 2.37 (1.82–3.07)< 0.001 1.61 (1.05–2.46) 0.029
Calcium <30d
Hormone 1 1 1 0
Non-hormone 11 11 11 11
OR (95% CI) p 0.97 (0.28–3.35) 0.959 2.78 (0.64–12.05) 0.172 1.21 (0.41–3.55) 0.732 3.60 (1.12–11.56) 0.031
Calcium ≥30d
Hormone 12 2 10 0
Non-hormone 29 29 29 29
OR (95% CI) p 1.98 (1.12–3.50) 0.019 2.9 (0.90–9.43) 0.075 1.21 (0.65–2.26) 0.555 1.85 (0.59–5.82) 0.293
Bisphosphonate <30d
Hormone 1 0 0 0
Non-hormone 3 3 3 3
OR (95% CI) p 3.05 (0.70–13.42) 0.139 - (−) 0.999 - (−) 0.999 1.50 (0.14–15.69) 0.737
Bisphosphonate ≥30d
Hormone 6 2 7 0
Non-hormone 18 18 18 18
OR (95% CI) p 1.96 (0.94–4.12) 0.074 1.70 (0.40–7.19) 0.474 2.01 (0.93–4.73) 0.075 1.38 (0.29–6.60) 0.685
This table shows the number of prospective PPI users for hormone replacement use and non-use.
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unclear which of these, if any, may be a contributory fac-
tor in the possible interaction between NSAIDs and
tibolone. This study did not assess whether the effects of
NSAIDs on tibolone users and their risk of GORD were
mediated by the type of NSAID drug. Naproxen is
thought to be more gastrotoxic than ibuprofen and
diclofenac; whether this holds true for the potential
interaction with tibolone remains to be established. In
this study, the term GORD relates to a range of GORD
like symptoms; it is possible to suggest that the associ-
ation between NSAID and GORD may be related to gas-
trotoxicity, and not to an increase in ‘true’ GORD.
The use of HRT declined following publicity about
its possible association with cancer and cardiovascular
disease [30,31]. However, these data go some way to
explain the risk of GORD and PPI use in this group
and also provide a possible explanation for those now
on HRT who may have GORD symptoms. The GP
records used in this study may be a more reliable
mechanism for recording GORD symptoms than self-
reporting methods used in other studies; this may
explain the slightly higher level of risk identified in this
study compared to other cohort studies [32]. Our find-
ings are likely to be an underestimate of the extent of
the problem as many women who chose not to consult
for GORD may simply have stopped taking hormone
therapy and would therefore be excluded or miscoded
in our analysis. Many women might have also have
wanted to avoid polypharmacy. Up to 75% of women
choose to stop using HRT in the first six months [33]
as a result of reported side effects including weight
gain, headache, nausea and perceptions of disease risk.
While the design of most studies prevents further ana-
lysis of side effects [30], it is possible that at least a
proportion of these were attributable to GORD. Our
findings, if validated in a prospective study, may have
important consequences for the management and
resources used by patients with upper GI symptoms as
these patients would normally constitute a higher use
group for acid suppression therapy.
Study limitations
The GPRD inconsistently records endoscopy findings;
because of the lack of secondary care data to verify the
presence of GORD, there is a potential risk of misclassi-
fication. The current study explored the relationship be-
tween HRT and GORD as presenting to and clinically
diagnosed by GPs. This is increasingly the only relevant
definition at a time when GPs no longer routinely refer
patients without alarm signs for endoscopy because of
the perceived balance of risks and benefits to these low-
risk patients. Because of well acknowledged difficulties
in classifying GORD, this study compared a broad defin-
ition of GORD encompassing symptoms such as
waterbrash, with a more specific definition of ICD 10
codes (K21) indicative of a GORD diagnosis. Simple re-
gression was conducted using both definitions: the simi-
larity of findings strengthens the conclusions. The
GPRD records used in this study may in fact be a more
reliable mechanism for recording GORD symptoms than
self-reporting methods used in other studies.
Given the weaknesses inherent in GORD recording,
we also investigated PPI use in this cohort. Although
most of the PPI users had a record of GORD, PPI has
many other uses. In addition, many patients with GORD
were not prescribed PPIs and it is likely that many
women suffering side-effects of HRT would not immedi-
ately commence PPIs. We therefore treated GORD suf-
ferers and PPI users as two separate ‘proxy’ groups. The
fact that findings were similar across these groups
strengthens the association between oestrogen-only
HRT and GORD.
When seeking causative associations, weaknesses in-
herent in all observational design are the problem of un-
measured variables, and the difficulties in teasing out
temporal relationships. The similarity of hormone users
and non-users at baseline and the consistency of effect
with different model formulations offers some protection
against this. Selection bias is another common threat to
validity although in this study GPRD data was collected
from a wide cross-section of general practices from
across the UK. It is not possible to rule out some under-
lying factor selecting patients who do and don’t receive
HRT which is GORD-related, although there is no evi-
dence for this.
A further potential weakness of any GPRD study is
the incompleteness of BMI, smoking and alcohol data
due to the fact that most general practices do not rou-
tinely and systematically collect this data. For example,
only 41% of women had any BMI record within the
study window (erroneous range 0.5 to 896000); after
data cleaning, only 21% of BMI records were within
acceptable limits. The association between these
variables and GORD are well established and so in
order to understand their relative effect in combin-
ation with HRT use, we conducted sub-group analysis
on complete cases. Our findings showed that the
strength of association with HRT remained the same
as in the wider group but because numbers were small,
a prospective study design would be required to con-
firm these findings.
A further limitation of the study, that might weaken
the strength of association, is the lack of a direct meas-
ure of adherence to prescribed medication. Since HRT
may be used in varying doses over time for symptom
control, dose dependency could not be adequately exam-
ined using this data. We identified outcomes using diag-
nostic codes but we were unable to assess the severity of
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GORD symptoms or to assess whether compliance with
HRT was affected by the occurrence of GORD. Similarly
it was not possible to explore the association between
different hormone replacement therapies and the dose
or frequency of PPI use in a meaningful way.
Conclusions
There is a statistically significant independent associ-
ation between oestrogen-only hormone and GORD and
PPI use. Oestrogen-only hormone has a stronger inde-
pendent association with GORD than progestogen, re-
futing earlier in-vitro studies suggesting progestogen was
the most important hormone in GORD aetiology. The
known association between NSAID and GORD appears
higher in magnitude with tibolone use than other hor-
mone use but was not found to be statistically signifi-
cant. This should be further investigated using
prospective follow-up to examine the strength of associ-
ation and describe its clinical significance.
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